The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia

Autor: Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel PM, Wang S, Richarz U, Gopal S, Kane JM

Publikováno v: Neuropsychiatric Disease and Treatment, Vol Volume 19, Pp 531-545 (2023)

Ruth Milz,1 Carmela Benson,1 Karl Knight,1 Jose Antunes,2 Dean Najarian,3 Paola-Maria Lopez Rengel,4 Steven Wang,1 Ute Richarz,5 Srihari Gopal,1 John M Kane6,7 1Janssen Research & Development LLC, Titusville, NJ, USA; 2Janssen-Cilag, Porto Salvo, Por

Externí odkaz: https://doaj.org/article/ccd96ec2994a4a2f87af066a413b68ba

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

Autor: Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S

Publikováno v: Neuropsychiatric Disease and Treatment, Vol Volume 14, Pp 2807-2816 (2018)

Maju Mathews,1 Isaac Nuamah,1 Adam J Savitz,1 David W Hough,1 Dean Najarian,2 Edward Kim,2 Srihari Gopal1 1Janssen Research and Development, LLC, Titusville, NJ, USA; 2Janssen Scientific Affairs, Titusville, LLC, NJ, USA Objective: The aim of this st

Externí odkaz: https://doaj.org/article/65792ee977724b2386b52b08d8e5f73b

Rapid Separation and Purification of Oligonucleotides by High-Performance Capillary Gel Electrophoresis

Autor: Cohen, A. S., Najarian, D. R., Paulus, A., Guttman, A., Smith, John A., Karger, B. L.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 1988 Dec . 85(24), 9660-9663.

Externí odkaz: https://www.jstor.org/stable/32696

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.

Autor: Najarian D; Janssen Scientific Affairs, LLC, New Jersey, USA., Sanga P; Janssen Research and Development LLC, New Jersey, USA., Wang S; Janssen Research and Development LLC, New Jersey, USA., Lim P; Janssen Research and Development LLC, New Jersey, USA., Singh A; Janssen Research and Development LLC, New Jersey, USA., Robertson MJ; Janssen Research and Development LLC, New Jersey, USA., Cohen K; Janssen Research and Development LLC, New Jersey, USA., Schotte A; Janssen Research and Development, Beerse, Belgium., Milz R; Janssen-Cilag, Neuss, Germany., Venkatasubramanian R; Janssen Research and Development LLC, New Jersey, USA., T'Jollyn H; Janssen Research and Development, Beerse, Belgium., Walling DP; CNS Network, LLC, Garden Grove, California, USA., Galderisi S; University of Campania 'Luigi Vanvitelli,' Naples, Italy., Gopal S; Janssen Research and Development LLC, New Jersey, USA.

Publikováno v: The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2022 Mar 17; Vol. 25 (3), pp. 238-251.

Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N -Acetylgalactosamine-Conjugated RNA Interference Therapeutic.

Autor: Li J; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Liu J; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Zhang X; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Clausen V; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Tran C; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Arciprete M; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Wang Q; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Rocca C; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Guan LH; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Zhang G; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Najarian D; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Xu Y; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Smith P; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Wu JT; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts., Chong S; Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts schong@alnylam.com.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2021 Jul; Vol. 49 (7), pp. 572-580. Date of Electronic Publication: 2021 May 03.